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Issues in Biochemical Applications to Risk
Assessment: How Should the MTD Be
Selected for Chronic Bioassays?
by R. J. Kociba*
Introduction
The topic assigned to me was phrased in the form of
a question that read, "How should the MTD be selected
for chronic bioassays?" As a prelude, the response to
the question warrants a brief review of the historical
evolution ofthis issue.
Table 1 is a summary ofthe historical chronology by
which the dose selection process has evolved over the
past 30 years. In the early to mid-1950s, the major
emphasis was in the evaluation ofchronic organtoxicity
rather than carcinogenicity, and estimates of potential
human exposure were factored into the dose selection
processfortheanimalstudies. Intheearlytomid-1960s,
the emphasis shifted to the use.of exaggerated (some-
times lethal) doses forthe purpose of a short-term qual-
itativescreeningevaluationofcarcinogenicitypotential.
This time period was characterized by the use of a rel-
ativelycrude basisfordose selection, withthe emphasis
on mortality and frank body weight loss. In the early
to mid-1970s, the availability oflaboratory animals with
better survival led to the lengthening of the duration
ofdosing with the maximal dose levels compatible with
survival of a sufficient number of animals. This time
period saw some slight improvements in the relatively
crude basis for dose selection.
In the early to mid-1980s, there was a carryover of
some ofthe previous philosophy, but with arecognition
ofthe need for a more scientifically valid basis for dose
selection. This time period has been characterized by
the need for (a) more definitive subchronic studies, (b)
definition and recognition of the critical role played by
dose-related changes in kinetics, and (c) the recognition
of the need to avoid dose levels that create nonphysio-
logical conditions oftreatment. Thus, it is apparent that
this issue ofdose selection forchronic toxicity and onco-
genicity studies has been and continues to be a topic of
debate and controversy. I believe this issue of dose
selections remains the most challenging aspect ofstudy
design, anditsimportanceisunderscoredbythe current
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Table 1. Summary chronology of high-dose selection process.
Time period Guideline for high-dose selection
Early to mid 1950s Major emphasis on chronic toxicity rather
than carcinogenicity
Estimates ofhuman exposure factored into
procedures
Early to mid 1960s Use of exaggerated (lethal) doses for
qualitative screening of carcinogenicity
potential
Crude basis for dose selection
Early to mid 1970s Lengthening of duration of dosing with
maximal doses compatible with long-term
survival of sufficient numbers of animals
Slight improvements in crude basis for dose
selection
Early to mid 1980s Carryover of previous philosophy, but
recognition of need for more scientifically
valid basis of dose selection
More definitive subchronic studies
Critical role of dose-related kinetics
Avoidance ofnonphysiological conditions of
treatment
Recognition of the need for relevance to
known or anticipated levels of human
exposure
format of addressing both chronic toxicity and onco-
genicitypotentialinoneandthesamejointstudy. Based
on the consideration of the extensive human and phys-
icalresources thatmustbeappropriated forthe conduct
ofthese long-term toxicity studies, it is imperative that
we strive to maximize the yield from these efforts by
conducting the most scientifically sound type ofstudies
specifically designed tojointly address both chronictox-
icity and oncogenicity. The subsequent interpretation
ofthe study results is also greatly facilitated by the use
of an optimal joint study design wherein it is more fea-
sible to evaluate any possible mechanistic relationships
between chronic toxicity and observed oncogenic
responses. Based on these factors, it is recommended
that future study designs continue to jointly address
both chronic toxicity and oncogenic potential.
There is considerable merit in restating the basic
premise and rationale that serves as the driving force
to warrant the conduct ofthese studies. Simply stated,R. J. KOCIBA
these long-term animal studies are conducted to gen-
erate both qualitative and quantitative dose-response
data that are useful via extrapolation to the evaluation
of potential human risk associated with known or an-
ticipated level(s) ofexposure byhumans. Asstated, this
definition of the basic rationale stresses not only the
qualitative and quantitative aspects ofthe animal dose-
response data, but also the known or anticipated levels
of exposure by humans.
Figure 1 graphically depicts the spectrum ofbiologic
responses typically defined in a subchronic or chronic
animaltoxicity study. The spectrumofbiologicresponse
typically spans agraded series ofincreasingdose levels
thatrangesfromalowerdose levelatwhichnoresponse
is elicited (the No-Observed-Effect-Level, or NOEL),
to a slightly higher dose level at which we may observe
an adaptive physiologicresponse (the No-Observed-Ad-
verse-Effect-Level, orNOAEL), to increasingly higher
dose levels that will define the Lowest-Observed-Ef-
fect-Level (LOEL) and also the Frank-Effect-Level
(FEL). As depicted in the lower portion of Figure 1,
the high dose selected for the chronic toxicity study
typically represents a point selected along the range of
those dose levels extending from LOEL-LOAEL-
FEL. The specific points along this spectrum that will
be selected as the high-dose level remains a point of
controversy and debate among toxicologists and pa-
thologists. Some scientists recommend selection of a
maximally tolerated dose or MTD that is in the range
of the FEL, based on the premise that the principal
limiting factor should be based on survival of an ade-
quate number of test animals to allow statistical anal-
yses ofthe data. Other scientists recommend selection
of a high-dose level that is in the range of the LOEL
or LOAEL, based on the premise that this type ofdose
selection more adequately generates data that is more
readily applicable to the low-dose extrapolation process
for human exposure.
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Table 2 lists the perceived advantages and disadvan-
tages currently associated withthe selectionofmaximal
tolerated doses for chronic animal bioassays. Propo-
nents of high-dose testing use the primary argument
that these bioassays are relatively insensitive for de-
tecting carcinogenic effects. Other scientists express
concern over the disadvantages of MTD testing, such
as metabolic overload and lack of relevance for safety
assessment of human exposure.
Table3 depicts the keyfactorsthatarerecommended
as the basis for my response to the question of high-
dose selection for chronic animal bioassays. Concep-
tually, it is imperative that the discipline oftoxicology
strive to utilize the best available technology of the
1980s for high-dose selection. Operationally, this wili
requirethattheparameters evaluatedinthe subchronic
(and chronic) dose-response studies mustbe sufficiently
comprehensive to supplement the relatively crude pa-
rameters used historically in high-dose selection. Based
on conventional clinical and morphologic parameters,
the high dose level selected for the chronic studies
Table 2. Examples of current debate concerning the use of
maximum tolerated doses (MTD) for chronic animal bioassays.
Perceived advantages
of MTD testing
"The primary argument for
support of MTD testing is
that current testing
protocols (including the
MTD) are known to be
relatively insensitive for
detecting carcinogenic
effects" (1).
"More than two-thirds ofthe
carcinogenic effects
detected in feeding studies
would have been missed
had the high dose been
reduced from the estimated
MTD to 1/2 MTD" (1).
FEL
_j
General range ofdose selected as high
dose level for chronic toxicity/
oncogenicity studies
FIGURE 1. Spectrum of biologic responses elicited in subehronic/
chronic toxicity studies. NOEL, No-Observed-Effect Level;
NOAEL, No-Observed-Adverse-Effect Level; LOEL, Lowest-
Observed-Effect Level; LOAEL, Lowest-Observed-Adverse-Ef-
fect Level; FEL, Frank Effect Level.
Perceived disadvantages
of MTD testing
"Largest doses (far exceeding human
exposure levels) has been strongly
recommended... in order to
overcome the inherent low
sensitivity ofbioassays. These
recommendations have been
controversial because high doses
may themselves produce altered
physiologic conditions which can
qualitatively affect the induction of
malignant tumors" (2).
"Further bias is introduced by
prescribing 'nearly toxic' or
'maximally tolerated' doses ofthe
test substance, i.e., doses that
potentially overload these
metabolic pathways that might
influence the development of a
tumor" (3).
"To slavishly endorse the MTD is to
ignore the only purpose ofthe
study: develop some
understanding ofrisk/benefit at
real exposure limits" (4).
"The use ofthe MTD is an
anachronism" (4).
"The MTD might be an excessive
multitude ofthe human exposure.
We have examples where the
MTD is 30,000x the human
exposure" (4).
"Nonsensical academic exercise...
... Tumors (or anything else)
observed at these doses are
essentially irrelevant to safety
considerations for man" (5).
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Table 3. Recommendations for selection of high dose levels for
chronic animal bioassays.
Conceptually, the discipline of toxicology must strive to utilize the
best available technology of the 1980s for high-dose selection
The parameters evaluated in the subchronic (and chronic) dose-
response studies must be sufficiently comprehensive to supplement
the crude parameters used historically to define the MTD
Detailed histopathology
Hematology, urinalysis, clinical chemistry
Organ weights
Specific tests, dictated by mechanism ofaction oftest compound
Methemoglobin
Acetylcholinesterase
Others
Optimal choice ofhigh dose level for chronic study should be that
dose which in subchronic study elicited discernible but slight
degree of toxicity
Sufficient metabolism and kinetic studies must be prospectively
conducted to allow selection of high dose levels that:
Are within the range of linear dose-dependent kinetics
Avoid metabolic overdose
Factor in the known or anticipated levels of human exposure
should represent that dose level which elicited some
discernible but slight degree of toxicity in the sub-
chronic studies. Good science (and humane reasons) dic-
tates against the selection ofhigher dose levels for the
chronic studies that exceed that dose level which in the
subehronic studies has elicited a discernible but slight
degree of toxicity.
We must also prospectively conduct sufficient metab-
olism and kinetic studies that allow selection of high-
dose levels that are (a) within the range of linear dose-
response kinetics, and (b) avoid metabolic overdosing.
Finally, we must factor in the data on the known or
anticipated levels of human exposure associated with
the substance. It is only through the use of these rec-
ommendations that the discipline oftoxicology can pro-
fess to be applying the best available technology ofthe
1980s to the issue at hand, namely, selection of high-
dose levels that are scientifically appropriate and useful
for the subsequent extrapolation to human exposure
scenarios.
Discussion
DR. RoY ALBERT, UNIVERSITY OF CINCINNATI
MEDICAL CENTER: I thinkit'sgenerallyrecognizedthat
a bioassay is trying to do two things at once, which are
in a sense mutually incompatible: first, to answer the
question as to whether the agent is a carcinogen, sec-
ond, to get a handle on the nature ofthe dose response
as a basis for extrapolation to low levels. I wonder
whether or not we haven't been drawn into an exceed-
ingly expensive and anonoptimallyproductive approach
to this by the conventional elaborate bioassay tech-
nique. And I wonder whether or not we ought to roll
back the clock a little bit, as you indicated in one ofyour
earlier slides, and do screening studies for carcinogenic
response at very high doses for MTD.
Carcinogens are by and large pretty toxic materials.
And ifyou really want to be sure whether or not you're
goingtogetacarcinogenicresponse, yougenerallywant
to aim for exposures that are really in the toxic range.
Having done a relatively abbreviated form ofscreening
for the existence of carcinogenic response, this then
could serve as a springboard for the much more elab-
orate dose-response type of bioassay, which is very
costly, and which would provide the basis for making
judgments as to how the agent is to be dealt with in a
regulatory framework.
The question I'm raising has to do with the overall
efficiency of our searching out carcinogens in the en-
vironment. It's been said ad nauseam that there are in
the order of60,000 chemicals that are in circulation. We
have examined perhaps 10% ofthese agents. Wouldn't
it be better to fall back on screening approaches for
carcinogens and limit the bioassays to those that show
up positive in screening rather than trying to do every-
thingat once at acost ofahalf-a-million dollars athrow?
DR. KoCIBA: I have an answer I'd like to give to that,
but before I respond I'll give other people in the audi-
ence a chance to give their opinion on this very timely
question that Dr. Albert has raised.
DR. RAJENDRA CHHABRA, NIEHS: I don't have
many comments. I'm just asking about some of your
definitions. What is adaptive physiological response
compared to no response? How one determines what is
adaptive physiological response?
DR. KocIBA: I'll answer your question first and then
we'll come backto Roy's because I think Roy has a very
pertinent question. In response to that question, in my
opinion, the adaptive type of response has to be ob-
viously looked at on a very specific case-by-case basis.
I know of no general rule that I could give you or that
anyone could give you that would serve 100% of the
time. I'm thinking along the lines of enzyme induction
in hepatocytes in the absence ofaccompanying cytotox-
icity and this sort ofthing as an adaptive response.
DR. CHHABRA: If we find in one group of animals
there's aslightinduction ofdrug-metabolizingenzymes,
in another group there isn't, is the one group which has
got slight induction of drug-metabolizing enzymes an
adaptive physiological response?
DR. KoCIBA: It could be.
DR. CHHABRA: So would that dose be selected as a
high dose?
DR. KocIBA: It may or may not be. Like I say, I
know of no general rule or generic rule one could use
there. I think you would have to look at the full data
base, and therein would lie the advantage ofhaving as
comprehensive a data package as you have. This would
be not only data from your subchronic studies that
would allowyoutointerpretthoseobservationsandlook
at a dose response, but also use what data we have on
kinetics to see is there a break in the linearity of the
curve that would correlate with some of these things.
DR. CHHABRA: I agree with you. My second question
is what are the nonphysiological conditions of treat-
ment?
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DR. KoCIBA: You're questioning some of the termi-
nology used in the literature?
DR. CHHABRA: Yes. I'd just like to make it clear to
myself.
DR. KOcIBA: Well, I think what people have been
trying to do in the literature is to group together all of
those components that come into play as you scale up
the doses up into a range in which you have exceeded
the normal metabolic capacities inherent within that
organism. Somewhere along the line those are going to
be exceeded. And I think that's the meaning that some
of the people I've cited there have had in mind when
they use the term nonphysiologic conditions.
DR. CHHABRA: And anything you use, dose lower
than that, that's within physiological conditions?
DR. KOCIBA: Well, that's what your dose response
would tell you.
DR. CHHABRA: And one last question. How do you
determine this slight degree of toxicity? You said that
for selection ofMTD you would have a slight degree of
toxicity. What is that slight degree of toxicity?
DR. KoCIBA: Again, that's going to depend on your
case-by-case evaluation of the data set you have. And
you're going to be much better off if you have a com-
prehensive datapackage with yourcomplementary clin-
ical data, your organ weight data, your clinical obser-
vations, etc., to supplement the morphology. Too many
times I've seen the dose selection based entirely on
morphology and maybe abodyweightreduction. I think
those parameters are too crude. In the later 1980s that
we are now in I think we have the responsibility to
society at large to do a better job than we've done in
the past.
DR. CHHABRA: Okay. My pointforaskingthose three
questions was I think it would be a subjective decision
and it would be a sort of professional judgment on se-
lection of the high dose. There are no well-defined cri-
teria that can help us to determine what is slightly toxic
or what a nonphysiologic condition is, and what is ad-
aptation. So it would be mostly a professionaljudgment
in the selection of high dose MTD for carcinogenicity
studies, and it will vary from person to person. And
from chemical to chemical.
DR. KocIBA: Inmyexperience there have neverbeen
two compounds that were in essence two peas in the
same pod. You know, there might be some similarity.
But you have to consider each compound on its own
merits. And that's why I'm making the plea to have a
more comprehensive data package before we go about
selectingthose doselevels. Typically, thekinetic studies
are going to be conducted sooner or later. And my plea
is let's do these studies before we make that dose se-
lection rather than 3 years later when we're trying to
do it in retrospect.
DR. CHHABRA: But you cannot do kinetic studies on
all kinds of chemicals. It depends on the purity of the
chemical; a mixture ofchemicals cannot be subjected to
pharmacokinetic studies.
DR. KocIBA: Well, if there's that much interest in
subjecting it to a study that Dr. Albert says is going to
cost over a half-a-million dollars, I think we have to
rethink ourpriorities in regard to howwe allocate avail-
able resources for these different studies. Maybe it will
amount to testing fewer materials but doing a better
job on the ones we do study.
Before we go on to the next question, I'd like to go
back to Dr. Albert's very pertinent question here.
DR. MARSHALL ANDERSON, NIEHS: That's what I
wanted to go to. As Dr. Albert pointed out, the two
purposes aretotestwhetherthere'spotentialofachem-
ical to be a carcinogen at whatever dose, and extrapo-
lation to low doses. Let's forget about the species ex-
trapolation. I don't care how you set up the dose re-
sponse; if all you do is count tumors, you'll never do
low-dose extrapolation by just counting tumors on the
animal. I mean, I think NCTR's EDLI study proves
that point. How many chemicals could you test 50,000
animals with? So the only way that I think you're going
to scientifically extrapolate to low doses is by incorpo-
rating the mechanisms that we know about-at least
some ofthe steps we haveprettywelldefined. Youhave
to take these into account.
Looking at promutagenic lesions, you can go down to
doses to which humans are exposed. I think that should
be the approach rather than trying to design tumor
studies to get down to human exposure doses. I don't
think it's possible.
DR. KocIBA: Do you have a comment in regard to
what Dr. Albert spoke to?
DR. J. C. BHANDARI, DYNAMAC CORPORATION: Yes,
please. In response to Dr. Albert's question, a couple
ofyears ago the Society ofToxicologic Pathologists had
a symposium which was the design of carcinogenicity
studies. And in that one I had proposed the same idea
thatyoujustsuggestedbypresentingcertainexamples.
You could actually boost the dose up and save millions
and time. But there were a couple ofproblems with it.
An example came very easy. Vinyl chloride. At 1000
mg you can produce all the tumors you want to see at
4 months or you can wait 2 years or 18 months, say, at
50 [mg] or less. Many other drugs can produce good
adenomas in livers and so on within 3 months or 6
months depending on your doses and see a beautiful
nice correlation. And these are not counting dead also.
These are microscopicand convincingresults. Butthere
are two problems. One isjust because you are at a way
high dose there. In the regulatory agencies now their
approach is the benefit ofdoubt. When you have a pos-
itive now, you have 1000 or 3000 times of what would
be the human dose, as Dr. Kociba showed. Just because
you wanted to solve (whether or not it was carcino-
genic), you went that 1000 times or 3000 times and now
you've got a positive, whereas on the low doses you
could show perfect 50 on it. You've got a real problem
as far as the industrial point of view. It becomes very
difficult toconvincetheregulatoryagenciesofthatpoint
now that you've got a 1000-fold of 50. So that's one
problem right there.
The second problem was how about the negative
ones? Positive ones, sure, you could save time and all
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that. But the negative ones, I wasn't concerned with it
because you got to do a study anyway. So if you can
show negative at 1000-fold, fine, you've done yourjob.
So negative really was not aproblem. Because negative
ones you won't save the time because you still have to
go 2 years. You cannot say, well, we'll be done in 6
months orsomething. Butatleastyouhaveprovenyour
point.
But I think the biggest problem was the regulatory
agencies have to accept that fact. Okay. Fine. If you
will show so much for safety, no problem. But that
doesn't happen in practice.
DR. KOCIBA: Well, I'll give my opinion in regard to
the question that Dr. Albert raised. I thinkifone would
go to a testing scheme where you would segregate out
carcinogenicity qualitative assessment from dose re-
sponse quantitative definition of organ toxicity and so
forth, I think you would create a dilemma that I think
was alluded to in the previous comments. If you did
your qualitative high dose abbreviated scaled-back kind
ofcarcinogenic assessment and thatstudy elicited apos-
itive response, this would automatically be put into the
unit risk estimate, and it would almost be a moot point
to spend the hundreds of thousands of dollars to do
anything in regard to the lower dose testing.
I personally endorse the concept ofincorporating the
oncogenicity and chronic toxicity into the same test.
And the reason for this is multiple. One of which it's
onlywhen we have the data fromthe same sort ofstudy
that we can make any association between precursor
lesions, cytotoxicity, hyperplastic lesions with the neo-
plastic process where it was observed. If we were to
segregate out these end points, we would lose that dis-
tinct option oftrying to make our interpretation on the
best basis, taking into account what precursor lesions
were occurring either at the same dose level that would
cause an oncogenic response, or, more importantly, at
lower dose levels is to see how steep that dose response
is in regard to the biological effect elicited. So person-
ally, I endorse the collaboration of looking at both the
chronic toxicity and oncogenicity in one and the same
study. And I think when you're all said and done, as
longas we continue to doitinthismannerusinganimals
and so forth, the cost would probably not be that much
different.
DR. BYRON BUTTERWORTH, CHEMICAL INDUSTRY
INSTITUTE OF TOXICOLOGY: I think when we're dealing
with compounds in the hundreds of milligrams per kil-
ogram per day region that the issues you've raised are
reasonable, and we all have to stick with what we're
dealingwith. I'mparticularly concerned, however, with
that very small subset ofchemicals where people go to
massive doses in order to get the tumors. I think we're
wasting resources and we're losing credibility. For ex-
ample, in the pharmaceutical industry, I've been told
overandoveragainthatifyou'redealingwithanontoxic
chemical that's in development you're in real trouble.
Because if reaching that maximum tolerated dose re-
quired thousands of milligrams per kilogram per day,
you invariably encounter some strange problem that's
a result ofthese unnatural conditions. For example, in
the NTP program that Ray [Tennant] talked about and
looking at that data that he presented at the Williams-
burg meeting, there were several chemicals that were
tested at doses in excess of6000 mg/kg/day. You really
have to wonder ifwe haven't gone offthe deep end for
those.
I would suggest that people that are involved with
this problem (Joe Haseman mentioned that he had a
problem with things that are going to be missed at
higher and lower doses) ifmaybe it wouldn't be a good
exercise to look at those chemicals which induce tumors
only at doses in excess of1000 mg/kg/day. And then ask
the question, Ifwe had chosen a thousand as the cutoff
and that would have been judged a carcinogen and we
would have done risk assessment based on other toxi-
cological parameters, would human health really have
been affected?
We really need to begin to focus on this small subset
because it's hurtingthe rest ofthe field. The compounds
that we deal with that are in the reasonable range, I
think we're doing all right. But this subset is really
killing us. And once again, I think that many of these
are going to be of the nongenotoxic variety. For ex-
ample, if you look at the NTP correlation study that
Ray talked about, those compounds that required in
excess of 500 mg/kg/day not a single one was a Sal-
monella mutagen.
Tyingthis back to Ray's final point, are there second-
class citizens? I don't think that he can say that non-
genotoxic carcinogens per se are less dangerous. Be-
cause there's TCDD and many others. However, ifyou
put two parameters together, if you say it's a nongen-
otoxic carcinogen and it required greater than 1000 mg/
kg/day to produce the tumor, then maybe you have a
candidate for some second-class citizens. That is to say,
chemicals which require less of our attention than
maybe some of the others.
DR. MICHAEL DIETER, NIEHS: As one ofthe chem-
icalmanagersinvolvedinthisprograminselectingthese
doses and trying to carry out these tests, I'd like to
make the remark that the other side is also valid. Just
as in the genotoxic tests, one of the things that should
be avoided is a possibility of a false negative. Just as
the example you cited, the chemical was used in very
high doses. There's another example that could be cited
just as well on the other side of the coin where the
chemical was tested in the tenths of parts per million
range and found to be completely negative in a 2-year
test. And when tested at tens orhundreds ofmilligrams
per kilogram in another test it was found to be carcin-
ogenic, causing multiple tumors in both sexes and both
species.
If you look at a scenario of this sort by selecting a
dose level, the highest of which only caused some sen-
sitivity responses in the treated animals in the pre-
chronic studies, you would have entirely missed a car-
cinogenic response by not selecting higher doses.
UNKNOWN SPEAKER: Let me respond. Don't get me
wrong. If you are dealing with tens of milligrams per
173174 R. J. KOCIBA
kilogram per day, surely you must deal with the issues
the way we have been dealing with them. I agree with
you. I'm talking about that set that's way over there
where you need over 1000 mg/kg/day. And then I chal-
lenge you to show me that we're dealing with the real
problem.
So it's not the ones that are in the range of, say, less
than a thousand. It's the ones greater than a thousand
where I thinkwe're losing credibility and we're wasting
resources.
DR. KOcIBA: Dr. Albert has motioned that we must
move on to the next paper. I want to thank everybody
for participating. I'm sure we could go on for 3 hr on
this issue.
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